Free General Oncology CE/CME

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | Texas Society of Clinical Oncology

Ajit K. Bisen, MD, MBA; Virginia Kaklamani, MD, DSc

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – North Carolina

Syma Iqbal, MD; Benjamin Scheier, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Minnesota

Geoffrey Ku, MD; Jack W. Erter III, MD, MMHC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | South Carolina Oncology Society

Kamel Abou Hussein, MD; Kate Baxstrom, MD

BURST CME™ Activity 3: Exploring Combination Strategies in HR+/HER2– MBC: Where Do Oral SERDs Fit In?

Erica L. Mayer, MD, MPH; Jason Aboudi Mouabbi, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – West Virginia

Sunnie S. Kim, MD; Kellie D. Spector, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Iowa Oncology Society

Aditya Bardia, MD, MPH, FASCO; Priya Kumar, MBBS, MS

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Empire State Hematology & Oncology Society

Aditya Bardia, MD, MPH, FASCO; Mohammad F. Ali, MD

Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Rajwanth Veluswamy, MD, MSCR; Alison Schram, MD; Brian M. Wolpin, MD, MPH

Community Oncology Connections™: Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Webinar Series

Annual Hematology Meeting Preceding the 68th ASH Annual Meeting and Exposition

December 11, 2026

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

The ADC Revolution in Metastatic Breast Cancer: Redefining Treatment Selection and Sequencing

Seth A. Wander, MD, PhD; Reshma L. Mahtani, DO; Shanu Modi, MD; Joyce O’Sha…

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne…

Advancing Targeted Therapy in HR+/HER2– Metastatic Breast Cancer: Integrating Next-Generation Endocrine and PAM-Pathway Strategies Into Practice

Joyce O’Shaughnessy, MD; Sarat Chandarlapaty, MD, PhD; Mitchell Elliott, MD…

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FA…

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

Community Practice Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma

Geoffrey Ku, MD; Sunnie S. Kim, MD

Satellite Symposia at the Annual Radiation Oncology Meeting

September 27-28, 2026

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Syma Iqbal, MD; Benjamin Scheier, MD

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

John O. Mascarenhas, MD; Claire Harrison, MD, DM, FRCP, FRCPath; Raajit Ram…

Community Practice Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO; Kamel Abou Hussein, MD

BURST CME™ Activity 2: Oral SERD Monotherapy: Understanding the Evidence Base

Adam Brufsky, MD, PhD; Manali Bhave, MD

BURST CME™ Activity 1: Foundations of Endocrine Resistance and Oral SERDs in HR+/HER2– Metastatic Breast Cancer

Adam Brufsky, MD, PhD; Manali Bhave, MD

ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions

William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisbe…

Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care

Benjamin P. Levy, MD; Sarah Goldberg, MD, MPH; Jacob Sands, MD; Helena Yu, …

Cure to Cancer Survivorship: A New Era of Biomarkers, Interventions, and Care Models

February 6, 2027

Live Tumor Board: Exploring Novel Targets and Breakthrough Treatment Strategies in Extrapulmonary Neuroendocrine Carcinomas

Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, PhD

Medical Crossfire®: DLL3-Directed Therapies in Small Cell Lung Cancer—A Nursing-Centered Approach to a New Era of Care

Alissa J. Cooper, MD; Kelly Goodwin, NP; Stephanie J. McDonald, MSN, FNP-BC…

Medical Crossfire®: Turning Therapeutic Innovation Into Practice—Personalizing Care in Multiple Myeloma

Mohamad Mohty, MD, PhD; Shaji K. Kumar, MD; Suzanne Lentzsch, MD, PhD; Phil…

Live Tumor Board: Translating Biomarker Insights and Therapeutic Advances Into Endometrial Cancer Practice

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA; Casey Cosgrove, MD;…

Rhode Island Oncology Society

2 Sessions are Available!

Oncology Town Hall: Translating the Latest Updates Into the Care of Patients With AML in Community Practice

Eunice Wang, MD; Hetty Carraway, MD, MBA; Naval G. Daver, MD

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, …

Medical Crossfire® — From Diagnostic Dilemmas to Potential Treatment Breakthroughs: Exploring Novel Targets for Extrapulmonary Neuroendocrine Carcinomas

David S. Klimstra, MD; Danielle A. Hutchings, MD; Nancy M. Joseph, MD, PhD;…

Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer

Sanja Dacic, MD, PhD; Soo-Ryum (Stewart) Yang, MD; Isabel Preeshagul, DO, M…

Virtual Hot Seat: How the Experts Target the PI3K/AKT/mTOR Pathway in HR+/HER2– Metastatic Breast Cancer

Rebecca Shatsky, MD; Maxwell Roger Lloyd, MD; Sarah Sammons, MD; Sherry She…

OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer

Joyce O’Shaughnessy, MD; Virginia Kaklamani, MD, DSc; Seth A. Wander, MD, P…

Cases and Conversations: Translating ctDNA Into Clinical Decisions in Breast Cancer

Neil M. Iyengar, MD; Kelly Elizabeth McCann, MD, PhD; Wassim Mchayleh, MD, …

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, M…

Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Medical Crossfire®: Redefining Frontline and Maintenance Strategies in HER2+ Metastatic Breast Cancer

Joyce O’Shaughnessy, MD; Reshma L. Mahtani, DO; Heather McArthur, MD, MPH; …